Intravenous (IV) Iron Drugs: Market Research Report

Date: January 1, 2015
Pages: 135
Price:
US$ 4,950.00
Publisher: Global Industry Analysts, Inc
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: I542C761285EN
Leaflet:

Download PDF Leaflet

Intravenous (IV) Iron Drugs: Market Research Report
This report analyzes the worldwide markets for Intravenous (IV) Iron Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 17 companies including many key and niche players such as -
  • Actavis, Inc.
  • AMAG Pharmaceuticals, Inc.
  • Fresenius Medical Care AG & Co. KGaA
  • Galenica Ltd.
  • Luitpold Pharmaceuticals, Inc.
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. OUTLOOK

IV Iron Drugs Market - A Quick Primer
US and Europe Dominate IV Iron Market
Asia-Pacific – The Fastest Growing Market
Recession Fails to Affect Market Growth
Positive Outlook for the Healthcare Industry Signals Prospects

Table 1. Healthcare Spending as a Percentage of GDP in Select Countries (includes corresponding Graph/Chart)

2. INDUSTRY OVERVIEW & TRENDS

IDA and Treatment – An Overview
Dialysis Clinics - Major Market for IV Iron Supplements

Table 2. World Distribution of Dialysis Patients by Country (2013): Number of Patients in Thousands for Brazil, China, Japan, Mexico, US and Others (includes corresponding Graph/Chart)
Table 3. World Dialysis Prevalence by Country (2013): Prevalence in Patients per Million Population for Brazil, China, Japan, Mexico, US and Others (includes corresponding Graph/Chart)
Table 4. Global Iron Deficiency Anemia Prevalence by Risk Groups - Preschool Children, School-age Children, Pregnant Women, Non-Pregnant Women, Men and Elderly Analyzed by Prevalence Percentage (includes corresponding Graph/Chart)
Table 5. Iron Deficiency Prevalence by Disease: Analyzed by Percentage Number of Patients with ID and IDA in CKD (with dialysis), Non-Dialysis-CKD, Congestive Heart Failure, Chemotherapy Induced Anemia, Irritable Bowel Disease, Patient Blood Management (Surgery), Heavy Uterine Bleeding and Postpartum (OB-GYN) (includes corresponding Graph/Chart)

IV Iron Drugs – An Overview
Select IV Iron Drugs Prescribed for Iron Deficiency

Table 6. Global Sales of Select IV Iron Drugs in US$ Million: 2013 (includes corresponding Graph/Chart)

Galenica – The Global Leader in IV Iron
Venofer - Galenica’s Wonder Drug
Venofer Continues to Lose Ground
Ferinject/Injectafer – A Promising Revenue Spinner for Galenica
Feraheme Surges Ahead; Manufacturer Eyes Expansion of Indications
The Vulnerable Ageing Population Supports Demand

Table 7. Global Population Statistics for the 65+ Age Group (Male & Female) for Major Countries/Regions: 2013E (includes corresponding Graph/Chart)

Changing Preferences Favor IV Iron Drugs
Comparison of Ferrous Salts with IV Iron Therapy
Chronic Kidney Disease – The Predominant Growth Factor
Other Chronic Diseases with IDA Offer Prospects for IV Iron Drugs
Anemia in Heart Failure – A Market with Huge Potential
Chemotherapy Induced Anemia to Promote IV Iron Supplements

Table 8. Global Cancer Incidence by Region (2012): Number of New Cancer Cases for Asia-Pacific, Europe, North and South America, and Africa (includes corresponding Graph/Chart)

Correction of IDA in Pregnancy Signals Opportunities
Women’s Health – Key Growth Opportunity
Perioperative and Postoperative Anemia – A Niche Market Beckons
Adverse Reactions of IV Iron Preparations Raise Concerns
Peginesatide – A Possible Threat to IV Iron
Dosing Limitations Plague IV Iron Market
Select Therapeutic Areas and the Required Iron Doses

3. REGULATORY OVERVIEW

Increasing Trend towards Bundled Reimbursements
A Glimpse of Regulations in the US and Europe
Comparison of Approved Indications and Safety Warnings for Select FDA Approved IV Iron Drugs
Coverage of IV Iron and ESA in the Reimbursement Packages of Dialysis Services across Belgium, Germany, Netherlands, the UK, France, the US and Ontario, Canada

4. OVERVIEW OF INTRAVENOUS (IV) IRON DRUGS

Iron – A Vital Element
Iron-Deficiency Anemia
Intravenous Therapy
Patients of Chronic Illnesses, the Elderly and Women – The High Risk Population
Treatment for Iron Deficiency Anemia
Iron Requirement in Chronic Kidney Disease
Classification of Iron Deficiency in CKD
Treating Iron Deficiency in CKD Patients
Side Effects of Iron Supplementation in CKD
Methods of Restoring Iron
Oral Iron Therapy
IV Iron-Infusion Therapy
Intravenous (IV) Iron
Conditions for Receiving Iron Injections
Injection Procedure
Categories of Iron Injections
Suitability of IV Iron Preparation
Suitability of Regimen
Management of Iron Doses
Effectiveness of Iron Injection
Requirement of Test Dose
Adverse Effects of Iron Injections
Iron Therapy: Caution
Duration of Iron Infusion
Iron Overdose
Iron-Out-of-Balance Therapies
Blood Donation
Therapeutic Phlebotomy
Red Cell Apheresis
Iron Chelation Therapy
Iron-Chelating Drugs
Desferrioxamine or Desferal
Deferiprone or Ferriprox
Conditions for Undergoing Iron Chelation Therapy
Kinds of Chelation Therapy
Side Effects Caused by IV Iron Chelation

5. PRODUCT LAUNCHES/APPROVALS

FDA approves Injectafer for the Treatment of IDA
Takeda Pharmaceutical Company Introduces Rienso in Europe
Pharmacosmos Launches Monofer Intravenous Iron Drug

6. RECENT INDUSTRY ACTIVITY

American Regent Steps Up Injectafer Promotions
AMAG Files for Rienso Label Expansion in Europe
AMAG Receives FDA Complete Response Letter for Feraheme
Vifor Pharma and Zeria Pharmaceutical Co. , Ltd. Sign Exclusive Licensing Agreement for Ferinject in Japan
Watson Pharmaceuticals Changes Name to Actavis
Luitpold Pharmaceuticals Obtains FDA Acceptance for Review of Injectafer NDA
AMAG Pharmaceuticals Receives FDA Acceptance for Feraheme sNDA Review
Takeda Issues Rienso Recall in Switzerland
EC Approves Takeda’s Rienso to Treat Anemia
BioLink Life Sciences to Commence Phase I Trial of FCP

7. FOCUS ON SELECT PLAYERS

Actavis, Inc. (US)
AMAG Pharmaceuticals, Inc. (US)
Fresenius Medical Care AG & Co. KGaA (Germany)
Galenica Ltd. (Switzerland)
Vifor Pharma Ltd. (Switzerland)
Luitpold Pharmaceuticals, Inc. (US)
American Regent, Inc. (US)
Pharmacosmos A/S (Denmark)
Sanofi US (US)
Takeda Pharmaceutical Company Limited (Japan)

8. GLOBAL MARKET PERSPECTIVE

Table 9. World Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 10. World Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 11. World 15-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

A. Market Analysis
Current & Future Analysis
CKD Fuels the US Market for IV Iron
Addressing Broader IDA Indicates Opportunities
CMS Reimbursement Shifts to Bundled Payment for Dialysis
Comparison of the Old (Fixed Payment) and Bundled Payment Reimbursement Models
The Anticipated Effect of Bundling Reimbursement on Clinical Practice
ESRD QIP Related Measures for the Years 2012, 2013 and 2014
Concerns over Allergic Reactions Prompts FDA to Issue Warning
Potential Short-Term and Long-Term Safety Concerns of IV Iron Preparations
Competitive Scenario

Table 12. Leading IV Iron Drugs in the US Market (2013): Percentage Breakdown of Value Sales for Feraheme, Ferrlecit, Venofer and Others (includes corresponding Graph/Chart)
Table 13. Leading Drugs in the US Non-Dialysis IV Iron Market (2011 & 2013): Percentage Breakdown of Volume Sales for Feraheme, Ferrlecit + Generic Ferric Gluconate, Venofer and Others (includes corresponding Graph/Chart)
Table 14. Iron Deficiency Prevalence by Disease: Analyzed by Percentage Share of Patients with ID and IDA for Select Diseases (includes corresponding Graph/Chart)
Table 15. Preferred Therapy for New ESRD Patients in the US: Percentage Breakdown by Number of Patients Opting for Hemodialysis, Transplant and Peritoneal Dialysis (includes corresponding Graph/Chart)

Does Dose Limitation Affect Venofer’s Sales?
Product Approval
Strategic Corporate Developments
Key Players
B. Market Analytics

Table 16. US Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 17. US Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

2. CANADA

Market Analysis

Table 18. Canadian Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 19. Canadian Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

3. JAPAN

A. Market Analysis
Current & Future Analysis
Market Overview
Bundled Payment Policy Encourages IV Iron Use
Strategic Corporate Development
Takeda Pharmaceutical Company Limited - A Key Player
B. Market Analytics

Table 20. Japanese Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 21. Japanese Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4. EUROPE

A. Market Analysis
Current & Future Analysis
Research Thrusts IV Iron Therapies into Limelight
List of Available IV Iron Drugs in Europe
An Overview of the Competitive Landscape

Table 22. Leading IV Iron Drugs in Europe (2013): Percentage Share Breakdown of Value Sales for Cosmofer, Ferinject, Ferrlecit/Gluconate, Generics, Iron Sucrose Similars (ISS), Venofer, and Others (includes corresponding Graph/Chart)

EMA Issues New Precautionary Guidelines for IV Iron Supplements
Product Launch
Strategic Corporate Developments
B. Market Analytics

Table 23. European Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region/Country - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 24. European Historic Review for Intravenous (IV) Iron Drugs by Geographic Region/Country - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 25. European 15-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region/Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4A. FRANCE

Market Analysis

Table 26. French Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 27. French Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4B. GERMANY

A. Market Analysis
Current & Future Analysis
Fresenius Medical Care Ag & Co. Kgaa – A Key Player
B. Market Analytics

Table 28. German Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 29. German Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4C. ITALY

Market Analysis

Table 30. Italian Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 31. Italian Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4D. THE UNITED KINGDOM

Market Analysis

Table 32. UK Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 33. UK Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4E. SPAIN

Market Analysis

Table 34. Spanish Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 35. Spanish Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4F. RUSSIA

Market Analysis

Table 36. Russian Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 37. Russian Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4G. REST OF EUROPE

A. Market Analysis
Current & Future Analysis
IV Iron Market in Switzerland

Table 38. Swiss IV Iron Market by Therapeutic Area: Percentage Breakdown of Value Sales for Cardiology, Gastroenterology, Geriatry, Gynaecology, Internal Medicine, Nephrology, Oncology, and Others (includes corresponding Graph/Chart)

Product Launch
Strategic Corporate Development
Key Players
B. Market Analytics

Table 39. Rest of European Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 40. Rest of European Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

Market Analysis

Table 41. Asia-Pacific Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region/Country - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 42. Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs by Geographic Region/Country - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 43. Asia-Pacific 15-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region/Country - Percentage Breakdown of Dollar Sales for China, India and Rest of Asia-Pacific Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

5A. CHINA

Market Analysis

Table 44. Chinese Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 45. Chinese Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

5B. INDIA

Market Analysis

Table 46. Indian Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 47. Indian Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

5C. REST OF ASIA-PACIFIC

Market Analysis

Table 48. Rest of Asia-Pacific Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 49. Rest of Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

6. LATIN AMERICA

Market Analysis

Table 50. Latin American Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - Brazil and Rest of Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 51. Latin American Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - Brazil and Rest of Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 52. Latin American 15-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for Brazil and Rest of Latin American Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

7. REST OF WORLD

Market Analysis

Table 53. Rest of World Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 54. Rest of World Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 17 (including Divisions/Subsidiaries - 20)
The United States (6)
Japan (2)
Europe (5)
  Germany (1)
  Rest of Europe (4)
Asia-Pacific (Excluding Japan) (7)
Skip to top


Ask Your Question

Intravenous (IV) Iron Drugs: Market Research Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: